跳至主要内容
临床试验/NCT02868255
NCT02868255已完成不适用

Myeloid Derived Suppressor Cells Control by SIRP-alpha: Investigation in Hepatocellular Carcinoma

Nantes University Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2016年1月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
1
主要终点
evaluation of the SIRP/CD47 expression

研究概览

简要总结

project is to study and develop anti-Signal Regulatory Protein α (SIRPα) antibodies (Ab) as a new immunotherapy strategy in cancer.

Samples harvested from hepatocellular carcinoma (HCC) and ovarian cancer patients will be used in evaluation of the SIRP-CD47 expression and of the effect of the anti-human Signal Regulatory Protein (hSIRP) Ab on various cellular types from patients and healthy volunteers.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • HCC patients (all BCLC stages accepted)
  • patient consent for the use of their biological samples

排除标准

  • patient with other cancers
  • hepatitis C or B positive
  • HCC treatment by chemo-embolization under 3 months
  • under Sorafenib treatment within the month prior to collection
  • underage or under guardianship patients

结局指标

主要结局

evaluation of the SIRP/CD47 expression

时间窗: baseline

samples harvested from HCC and ovarian cancer patients will be used in evaluation of the SIRP-CD47 expression and of the effect of the anti-hSIRP Ab on various cellular types from patients

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Myeloid Derived Suppressor Cells Control by Signal... | 临床试验